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THE ROLE OF GLUTAREDOXIN-1 ON B16F0 MELANOMA GROWTH AND 
ANGIOGENESIS IN DIET-INDUCED DIABETIC MICE 
BRIAN SUNG HO CHONG 
ABSTRACT 
Objectives: Recent studies have elucidated that diabetes mellitus (DM) patients exhibit 
an accelerated tumor progression, but the mechanism of its regulation is not yet fully 
understood. The following study seeks to examine the role of angiogenic factors in the 
growth of subcutaneously injected melanoma cancer using a diet-induced type II diabetic 
mouse model.	
Methods: C57BL/6 mice were fed either a regular or high-fat, high-sucrose (HFHS) diet 
for 2 months (T2DM model; confirmed through a GTT) and subcutaneously injected with 
B16F0 melanoma cells. After a 1-week or 2-week incubation period, the tumor was 
extracted to examine its size, weight, vascularity, and gene/protein expression. In vitro 
studies were performed using endothelial cells to assess the effects of high-glucose on 
endothelial cell proliferation, migration, and tube formation. GLRX expression was 
examined in both tumor samples and endothelial cells.	
Results: The results of the study showed that T2DM induced by a HFHS diet is able to 
promote tumor growth in both weight (2-week, p = 0.0070) and volume (1-week, p = 
0.0351; 2-week, p = 0.0002). Tumors extracted from the HFHS diet group showed 
reduced expressions of angiogenic markers (ACTA2 (1-week, p = 0.0239; 2-week, p = 
0.0123), KDR (1-week, p = 0.0091)) by western blot and a slightly reduced trend of 
angiogenesis (PECAM1) in histological analyses. GLRX expression was reduced in 
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HFHS tumor samples (1-week, p = 0.0090) and, interestingly, lower amounts of GSH 
adducts (2-week, p = 0.0317) could be seen in 2-week tumors as well. In vitro studies of 
endothelial cells showed reduced trends of endothelial cell function (proliferation, 
migration, and tube formation) in high glucose medium. Also, it has been observed that 
high glucose may be able to stimulate GLRX expression in endothelial cells. 
Conclusion: The results of the following study have confirmed that B16F0 melanoma 
growth is, in fact, augmented in diet-induced diabetic mice; however, the vascularity and 
levels of angiogenic markers from the tumor tissues did not parallel the growth in its size. 
In vitro studies suggested that high glucose can impair EC function (i.e. proliferation, 
migration, and tube formation capabilities) as well as promote GLRX expression, which 
may be related to this discrepancy. Glutaredoxin-1 (GLRX), an enzyme which controls 
redox signaling, is upregulated in DM. Endothelial cell-specific GLRX overexpression in 
transgenic mice was found to stimulate subcutaneously injected melanoma (B16F0) 
growth, despite hindering limb revascularization after hind limb ischemia. The 
augmented tumor progression in DM may be associated with GLRX upregulation, 
alongside impaired ischemic limb revascularization and tumor angiogenesis; however, 
the mechanism of tumor growth in diabetes still lies inconclusive and further studies need 
to be examined to elucidate this phenomenon. 
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INTRODUCTION 
 
 Diabetes mellitus (DM) is a chronic metabolic disorder that displays a broad 
spectrum of clinical manifestations in a variety of different organ systems. Of these, DM 
has been shown to exhibit higher rates of mortality with cancer (Barone et al., 2008) and 
augment the progression of certain types of neoplasms (Barone et al., 2010; Giovannucci 
et al., 2010; Nunez et al., 2006). Despite an indicated linkage between DM and 
augmented tumor progression, the pathogenesis of such nature is still obscure. The 
following study seeks to explore the role of angiogenic factors in the growth of 
subcutaneously injected melanoma cancer using a diet-induced type II diabetic mouse 
model. 
 
Type II Diabetes Mellitus (T2DM). 
 Diabetes mellitus (DM) is a metabolic disorder of various etiologies ranging from 
genetic to environmental factors. Clinically, diabetes is typically divided into two major 
types. Type I diabetes mellitus, previously referred to as juvenile-onset diabetes or 
insulin-dependent diabetes mellitus, is characterized by the body’s inability to produce 
insulin via the destruction of insulin-producing β-cells of the pancreas, most probably 
through viral or immunological mechanisms (American Diabetes Association, 2010). In 
contrast, type II diabetes mellitus (T2DM) was previously referred to as adult-onset 
diabetes or non-insulin-dependent diabetes mellitus and accounts for most of the 
diagnosed cases of diabetes (Centers for Disease Control and Prevention, 2017). T2DM 
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usually develops with insulin resistance and is postulated to be a result of both genetic 
and lifestyle factors (American Diabetes Association, 2010). 
 Accounting for approximately 90 to 95 % of all diagnosed cases of diabetes, 
T2DM has steadily increased in the number of its diagnosis and prevalence to become 
one of the most prevalent diseases in the modern-day society (Centers for Disease 
Control and Prevention, 2017). Among various complications which diabetes causes, this 
study aims to elucidate the relationship between the vascular complications and the 
augmented tumor progression exhibited in diabetes (Cheng & Ma, 2015; Giovannucci et 
al., 2010; Nunez et al., 2006). 
 
Vascular Complications of Diabetes. 
 DM is classically associated with two paradoxical complications in angiogenesis. 
There can either be a deficiency in the vascularization of peripheral tissues, which can 
lead to peripheral artery diseases (PAD) and critical limb ischemia (CLI), or an 
uncontrolled formation of premature blood vessels, such as in proliferative diabetic 
retinopathy (PDR) (Cheng & Ma, 2015). 
Critical limb ischemia is considered to be the end stage of PAD. PAD is typically 
initiated by obstructive atherosclerotic diseases; and poor arteriogenesis and angiogenesis 
potential (e.g. observed in diabetes) can cause severe necrotic cases, i.e. critical limb 
ischemia (Varu, Hogg, & Kibbe, 2010). In fact, it has been reported that 40 % of diabetic 
patients with CLI, compared with 9 % of nondiabetic patients, show a progression to 
gangrene and also have lower limb salvage rates compared to the latter (Varu et al., 
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2010), as diabetic patients with CLI showed a significantly higher risk, 5-years follow-
up, in major amputation rates with 34.1 % vs. 20.4 % (Spreen et al., 2016). 
 Previously, through an unpublished data, Dr. Colin Murdoch, Ph.D. (Vascular 
Biology Unit, BU School of Medicine) has shown that diet-induced diabetic mice 
exhibited significantly impaired revascularization (i.e. arteriogenesis and angiogenesis) 
after a hind limb ischemia procedure (Figure 1). 
 
 
Figure 1: Blood Flow Recovery (CD vs. HFHS). The blood flow recovery of diet-
induced diabetic (T2DM) mice was significantly impaired compared to the control (CD; 
normal chow) mice group. Blood flow ratio (y) was calculated using Doppler imaging of 
the ischemic limb / control. Ischemic hind limbs were generated on the left hind limb of 
the mouse through a femoral artery ligation procedure and compared to the control (right; 
non-ischemic) limb. Days (x) indicates the number of days, post-surgery. (* = p ≤ 0.05).  
 
 The results of the data suggest that T2DM, alone, can sufficiently inhibit 
arteriogenesis (collateral formation) and angiogenesis (capillary formation), in vivo. 
 Diabetic retinopathy is a medical condition in which damage occurs to the small 
blood vessels and neurons of the retina. The disease is classified into two types: non-
proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR). 
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NPDR is the early stage of the disease and symptoms include weakness in the blood 
vessels in the retina and microaneurysms (Duh, Sun, & Stitt, 2017). PDR is a progression 
of NPDR and, in contrast to the avascularity observed with NPDR, shows a rapid 
hypervascularity in fragile blood vessels through the expression of proangiogenic growth 
factors due to the hypoxic environment caused by circulation problems in the retina (Duh 
et al., 2017). In addition to being a pathological characteristic of microvascular 
complications in diabetes, persistent, uncontrolled angiogenesis is also a hallmark of 
cancer (Cheng & Ma, 2015; Krukovets, Legerski, Sul, & Stenina-Adognravi, 2015; 
Nishida, Yano, Nishida, Kamura, & Kojiro, 2006). 
 
The Role of Angiogenesis in Tumor Growth. 
 Multiple factors can contribute to tumor growth. However, tumor growth is 
classically thought to be inseparable with angiogenesis and neovascularization (Nishida 
et al., 2006; Ronca, Benkheil, Mitola, Struyf, & Liekens, 2017). That is, tumor growth, as 
is with any other tissue, should be angiogenesis-dependent, due to the high demand for 
nutrition from the rapidly proliferating cells. It is interesting to note that certain tumor 
cells, melanoma of the several, are also known to exhibit a phenomenon known as 
vasculogenic mimicry when they are unable to obtain sufficient nutrients from regular 
angiogenesis (Delgado-Bellido, Serrano-Saenz, Fernandez-Cortes, & Oliver, 2017; Qiao 
et al., 2015; Ronca et al., 2017). Vasculogenic mimicry is the de novo formation of vessel 
like structures without endothelial cells. These tumor cells are able to newly form and 
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line blood-carrying channels, effectively mimicking a true vascular endothelium 
(Delgado-Bellido et al., 2017; Qiao et al., 2015; Racordon et al., 2017). 
 
Tumor Progression in Diabetes. 
 As stated above, certain types of neoplasms (i.e. liver, pancreas, endometrium, 
colon and rectum, breast, and bladder) have been shown to exhibit a more aggressive 
progression with T2DM (Giovannucci et al., 2010). 
 Diabetes is a multifaceted metabolic syndrome as is the contributing factors that 
lead to tumor progression (Giovannucci et al., 2010; Vigneri, Frasca, Sciacca, Pandini, & 
Vigneri, 2009). Studies have tried to explain the enhanced tumor progression in diabetes 
with a plethora of different pathways from inflammation to insulin resistance (Chen et al., 
2014; Mori et al., 2006; Novosyadlyy et al., 2010; Nunez et al., 2006); however, the 
effects of angiogenesis on tumor growth in T2DM is not well explored. 
 
Glutaredoxin-1 Inhibits Endothelial Cell Migration. 
 Glutaredoxins are a class of redox enzymes that serve a vital role in cell signaling 
transduction pathways (Matsui, Watanabe, & Murdoch, 2017). Glutaredoxin-1 is a 
cytosolic enzyme that reduces post-translational modifications of GSH adducts in a GSH-
dependent manner. Reactive oxygen species (ROS) or reactive nitrogen species (RNS) 
induce thiolate anions to undergo S-hydroxylation or S-nitrosylation to produce sulfenic 
acid and S-nitrosothiol, respectively. These intermediate molecules are relatively 
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unstable, and are stabilized by reacting with glutathiones that are abundant in the cell, 
through a process called S-glutathionylation to produce glutathione adducts. GLRX 
reduces these GSH adducts back into reactive thiols (Matsui et al., 2017) (Figure 2). 
 
 
Figure 2: Glutaredoxin-1. Schematic diagram showing the role of glutaredoxin in the 
reversible modification of GSH adducts (Matsui et al., 2017). 
 
 Several studies have elucidated that GLRX inhibits endothelial cell migration 
through multiple targets within angiogenic pathways (Cohen et al., 2016; Matsui et al., 
2017; Murdoch et al., 2014; Watanabe et al., 2016). In short, GLRX has been shown to 
take part in pathways regarding nuclear factor kappa-B (NF-κB) transcription, hypoxia 
inducible factor 1 α (HIF1A) stabilization, protein tyrosine phosphatase 1B (PTP1B) 
activation, sarcoplasmic-endoplasmic reticulum calcium ATPase 2B (SERCA2) 
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inhibition, and Rac family small GTPase 1 (RAC1) activation by removing GSH adducts, 
leading to the inhibition of endothelial cell migration (Matsui et al., 2017) (Figure 3). 
 
 
Figure 3: Glutaredoxin-1 Inhibits Endothelial Cell Migration. Schematic diagram 
showing the various pathways that lead to attenuated EC migration (Matsui et al., 2017). 
 
 It is shown that GLRX is upregulated in diabetic rat tissue, and high glucose 
increases GLRX expression (Shelton, Kern, & Mieyal, 2007). GLRX is an NF-κB 
dependent gene (Aesif et al., 2011) and may be induced in expression by the 
inflammation associated with DM. Therefore, up-regulation of GLRX may contribute to 
the poor angiogenesis in DM and may influence tumor growth.  
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SPECIFIC AIMS 
 
 Type II diabetes mellitus and cancer are two of the most common type of illnesses 
that can significantly burden the quality of life in the modern-day society (Giovannucci et 
al., 2010). Although studies have indicated a linkage between type II diabetes mellitus 
and augmented tumor progression, the pathogenesis of such nature is still obscure 
(Vigneri et al., 2009). There are studies showing enhanced tumor growth in diabetic 
mice, but most of these studies examine the growth and metastasis of tumor cells using a 
type I diabetic mouse model. The vast majority of these studies do not focus on 
melanoma cells and a few examine tumor angiogenesis. 
 The following study aims to take a first look at subcutaneous B16F0 melanoma 
implant growth in diet-induced type II diabetic mice with the analysis of tumor 
vascularity and angiogenic factors. 
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METHODS 
 
Animal Model 
 8-weeks old, male C57BL/6 mice were either fed with a normal chow (NC) or a 
high-fat, high-sucrose (HFHS) diet for 2 or 3 months to generate control and T2DM 
models, respectively. The diabetic statuses of the mice were confirmed through a glucose 
tolerance test (Figure 4). Mice were intraperitoneally injected with D-glucose (1 mg/g of 
body weight) and monitored at specific time points for their blood glucose levels (Ayala 
et al., 2010). 
 
 
Figure 4: Glucose Tolerance Test (NC vs. HFHS). Glucose tolerance test of NC and 
HFHS mice. HFHS mice have a slower rate of glucose clearance, verifying diabetic 
status. (** = p ≤ 0.01, *** = p ≤ 0.001). 
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 Mouse models were generated in 4 separate cohorts. The preliminary, or pilot, 
cohort was created with n = 5 for each group and fed with special diet for 2 months. After 
feasibility studies were performed, 3 more cohorts were made with a 3-month diet. 
Cohorts 2 and 3 had their tumor extracted 2-weeks post-injection. Cohort 4 had their 
tumor extracted 1-week post-injection. 
 
B16F0 Melanoma Implants 
 B16F0 melanoma cells, obtained from Dr. Nader Rahimi, Ph.D. (BU School of 
Medicine), were cultured using Dulbecco’s Modified Eagle Medium (DMEM) (Gibco) 
with D-Glucose (4.5 g/L), L-Glutamine, and 10 % FBS. Cells were counted using a 
hemocytometer after being trypsinized using 0.25 % Trypsin-EDTA (Gibco) and 
suspended in Growth Factor Reduced Matrigel Basement Membrane Matrix (Corning). 
Syringes were prepared for injection with cells at a concentration of 4 ⋅ 105 cells / 200 µL 
of Matrigel per injection. 
 All injections were performed in the dedicated animal surgery room of the 
laboratory. The mice were anesthetized using ketamine and xylazine administered 
through an intraperitoneal injection for a final dose of 75 mg/kg and 8.5 mg/kg, 
respectively. Tumor implants were administered subcutaneously on the left caudal 
quadrant of the dorsum of the animal. The mice were monitored until they regained 
consciousness and returned to the BU animal facility for the remainder of the study. 
 Depending on their cohort, mice were brought back 1 or 2-weeks post-injection 
for sample collection. The mice were anesthetized using an IP-ketamine and xylazine 
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injection. From each mouse, the heart, lung, liver, skeletal muscle (gastrocnemius), and 
500 µL of serum were collected alongside tumor samples for future studies. 
 Mice were weighed before and after implantation and tumor samples were 
weighed and measured for their size using a digital caliper before being divided into 3 
pieces for frozen and paraffin sections and biochemical analyses. 
 Extracted tumor samples were calculated for their volume using the ellipsoid 
volume formula, V = π/6 ⋅ L ⋅ W ⋅ H (Tomayko & Reynolds, 1989). 
 
Human Dermal Microvascular Endothelial Cells 
 HDMVECn (ATCC) were cultured using EBM-2 (Lonza) basal medium with 
added EGM-2 MV SingleQuots (Lonza) kit, unless specified otherwise. The cells were 
supplied with fresh medium every 2 days and were passaged at approximately 80% 
confluence using 0.05 % Trypsin-EDTA (Gibco). 
 
Western Blot 
 Frozen tumor samples were pulverized in liquid nitrogen using a mortar and 
pestle to increase the homogeneity of the sample. Protein was extracted from 50 mg of 
tissue samples by centrifuging (4 °C; 30’; 13400 rpm) after homogenizing the samples in 
lysis buffer using a MagNA Lyser (Roche) instrument. 
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 Cellular proteins were extracted through centrifugation (4 °C; 30’; 13400 rpm) 
after the cells were scratched with lysis buffer using a cell scraper. Aspirated cell plates 
were frozen in liquid nitrogen prior to being scratched. 
 Protein concentration was determined using the DC Protein Assay (Bio Rad). 20 
µg of protein were run on NuPAGE 4 – 12 % Bis-Tris Gels (Invitrogen) and transferred 
onto TransBlot Turbo Mini-size PVDF Membranes (Bio Rad) using a Trans-Blot Turbo 
(Bio Rad) transfer system. Membranes were washed using PBS with Tween 20 (0.1 %) 
(PBS-T). After blocking with PBS-T containing 3% skim milk, primary antibody 
reactions were carried out in PBS-T with BSA (3 %). Secondary antibody reactions were 
done in PBS-T with skim milk (3 %). Membranes were developed using enhanced 
chemiluminescence with a digital KwikQuant (Kindle Biosciences) imager and 
quantified using ImageJ software (NIH). 
 
Immunohistochemistry 
 Immunohistochemistry analyses were performed using frozen and paraffin 
sections. Excised tumor samples for paraffin sections were fixed in 10 % formaldehyde 
overnight and transferred to PBS. Samples were embedded in paraffin and sectioned by 
the BU School of Medicine Immunohistochemistry Service Center. 
 Frozen sections were prepared by sequentially placing the tumor samples in PBS 
with 10 % sucrose, 20 % sucrose, and an even mixture of 20 % sucrose PBS with Tissue 
Plus Optimal Cutting Temperature (OCT) Compound (Fisher) embedding medium. 
Prepared samples were embedded in pure OCT Compound (Fisher) and sectioned using a 
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Leica CM1950 (Leica) cryostat. Sectioned samples were fixed using cold acetone and 
washed using PBS. The samples were blocked using a blocking solution (PBS-T with 3 
% BSA) and incubated with a diluted primary antibody overnight at 4 °C. Both primary 
and secondary antibodies were diluted in the blocking solution. Alexa Fluor 594-
conjugated secondary antibodies were applied at room temperature with Hoechst and 
incubated for 2 hours. Images were acquired using a Nikon deconvolution wide-field 
epifluorescence system (Nikon) in the BU core facility and analyzed using ImageJ 
software (NIH). 
 
RT-qPCR 
 Frozen tumor samples were pulverized in liquid nitrogen using a mortar and 
pestle to increase the homogeneity of the sample. mRNA was extracted from 50 mg of 
tissue samples using a Direct-zol RNA MiniPrep Plus (Zymo Research) kit. cDNA was 
synthesized from either 1 µg or 500 ng of mRNA using a iScript cDNA Synthesis Kit 
(Bio Rad). RT-qPCR was run using a CFX96 Touch Real-Time PCR Detection System 
(Bio Rad). 
 
Wound-healing Assay 
 HDMVEC were cultured in 0.5 % gelatin-coated plates until 80% confluence and 
made quiescent overnight using low-serum medium (EBM-2 basal medium with 0.1 % 
FBS), containing either low (1.0 g/L) or high (4.5 g/L) -glucose, without additional 
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growth-factors or cytokines. Scratch wounds were applied to endothelial cell monolayers 
using a sterile P-1000 pipette tip. Once scratched, cells were once again supplied with 
their respective low or high-glucose mediums with added vascular endothelial growth 
factor (VEGF; 50 ng/mL) (Murdoch et al., 2014). Images were taken at fixed locations 
along the wound at 0, 6, and 18 h using an Eclipse TS100 (Nikon) microscope with a 
SPOT Insight 2 MP CCD Color Digital Camera System (Spot Imaging). The images were 
analyzed with ImageJ software (NIH) by averaging the distances of 5 measurements per 
condition; this was considered as n = 1. 
 
Cell Proliferation Assay 
 Cell proliferation assays were performed using 96 well plates (Falcon). 
HDMVEC were seeded at a density of 1.8 ⋅ 103 cells / 45 µL / well. Once the cells were 
attached overnight, the cells were washed with PBS and had their medium changed to 
low (1.0 g/L) or high (4.5 g/L)-glucose medium. The cells were incubated for 4 days and 
their proliferation was measured using Hoechst staining, measured with an Infinite 
M1000 Pro (Tecan) multifunctional monochromator based microplate reader. 
 
Tube Formation Assay 
 96 well plates (Falcon) were coated with 40 µL of Growth Factor Reduced 
Matrigel Basement Membrane Matrix (Corning), and incubated at 37 °C for 1 hour. 
HDMVECn were seeded above the Matrigel matrix at a concentration of 1 ⋅ 104 cells / 45 
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µL of low (1.0 g/L) or high (4.5 g/L)-glucose medium per well. Photos of the cells were 
taken from 0 to 6 hours using an Eclipse TS100 (Nikon) microscope with a SPOT Insight 
2 MP CCD Color Digital Camera System (Spot Imaging) using a 40X view-field. Tube 
formation was quantified by using Angiogenesis Analyzer for ImageJ (NIH). In short, the 
images were skeletonized and analyzed for the number of nodes, junctions, meshes, 
segments, and branches; the lengths of the segments, branches, and the total length (sum 
of length of segments, isolated elements, and branches); and for the total area of the 
meshes. 
 
Hind Limb Ischemia 
 Hind limb ischemia surgeries and data were previously performed and collected 
by Dr. Colin Murdoch, Ph.D. (Vascular Biology Unit, BU School of Medicine). Briefly, 
ischemic limb revascularization was examined in NC and HFHS mice via a femoral 
artery ligation procedure followed by Doppler imaging (Murdoch et al., 2014). 
 
Statistical Analysis 
 All group data are expressed as means ± SEM. Statistical analysis comparing two 
groups were carried out using a parametric, unpaired t-test. p < 0.05 was used to 
determine significance. All analyses were carried out using GraphPad Prism 7 and 
Microsoft Excel. 
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RESULTS 
 
 
B16F0 Melanoma Growth is Significantly Promoted in Diabetic Mice. 
 Tumor masses excised from the HFHS group started to show an inclined tendency 
of growth from 1-week of incubation. The HFHS group had a slightly higher tumor 
weight (132.4 ± 15.23 mg, n = 4) compared to the NC group (98.45 ± 15.23 mg, n = 4) in 
1 week (Figure 5A, p = 0.1168). The volume of the tumor, estimated by the ellipsoid 
formula (Tomayko & Reynolds, 1989), was significantly different (p = 0.0351) between 
the two groups (NC vs. HFHS; 36.37 ± 7.219 mm3 vs. 101 ± 22.73 mm3, n = 4) (Figure 
5B). After 2 weeks of incubation (Cohorts 2 and 3), both the tumor weight (Figure 5C; p 
= 0.007) and volume (Figure 5D; p = 0.002) exhibited a significant difference between 
the two groups. The HFHS group had a larger tumor weight (1150 ± 147.6 mg, n = 7) and 
volume (1348 ± 161 mm3, n = 7) compared to the NC group, whose weight and volume 
were 678.5 ± 43.54 mg (n = 8) and 514.4 ± 59.02 mm3 (n = 8), respectively. The data of 
the tumor measurements suggest that the tumor size is significantly differentiated 
between the two groups within 1 to 2 weeks (Figures 5E, 5F). 
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Figure 5: Tumor Weight and Volume (NC vs. HFHS). (A) 1-week tumor weight of 
NC vs. HFHS mice (n = 4, each). (B) 1-week tumor volume of NC vs. HFHS mice (n = 
4, each). (C) 2-week tumor weight of NC vs. HFHS mice (n = 8 NC, n = 7 HFHS). (D) 2-
week tumor volume of NC vs. HFHS mice (n = 8 NC, n = 7 HFHS). (E) Tumor weight 
vs. incubation time (NC vs. HFHS). (F) Tumor volume vs. incubation time (NC vs. 
HFHS). (* = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001). See appendix for individual tumor 
size and weight data. 
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Vascular Density Assessed by PECAM1 was Not Significantly Different in the 
Melanoma Tumors from Both Diet Groups. 
 Upon excision of the tumor samples, vessel structures could be observed invading 
into the tumor masses from the host (Figure 6A), supplementing the notion that tumors 
are capable of initiating angiogenesis for growth (Nishida et al., 2006). 
 
 
Figure 6: Tumor Mass. (A) Image of vessel structures from the host invading into the 
tumor mass. (B) Representative image of extracted tumor sample. 
 
 Immunohistochemistry analyses were performed using immunofluorescent 
PECAM1 staining to quantify the vasculature density between the two groups. Tumor 
sections were photographed by stitching 9 view-fields of 100 X magnifications to create 
one large image (Figure 7). The sections were analyzed using ImageJ software (NIH) by 
normalizing the average the density of staining within 5 random areas per sample to the 
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area. The results showed that there was a slightly lower density of PECAM1 staining in 
the 2-week tumor samples (Cohort 2) of the HFHS group (1.342 ± 0.09972 %, n = 5) 
compared to the NC group (1.635 ± 0.1418 %, n = 5) (Figure 8); however, the results 
were not significant (p = 0.1291). 
 
 
Figure 7: Immunofluorescent PECAM1 Staining. Representative image of 
immunofluorescent PECAM1 staining used for vascular density analysis. PECAM1-
stained endothelial cells can be easily seen lining vessels in the magnified section (yellow 
box). Image of 2-week tumor (NC) vasculature. (large image bar = 500 µM; magnified 
image bar = 250 µM). 
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Figure 8: % Area of PECAM1 Staining (NC vs. HFHS). HFHS group shows slightly 
lower density of PECAM1 staining (p = 0.1291). 
 
Some Vascularity Markers Showed a Lower Trend of Expression in Tumors from 
Diabetic Mice. 
 Western blots performed on the tumor samples showed different results 
depending on the time-course and the cohort of mice. 1-week tumors (n = 4, each) 
showed the following expression of proteins (Figure 9A). Of interest, the expressions of 
ACTA2 (NC vs. HFHS; 1 ± 0.1328 vs. 0.495 ± 0.103, p = 0.0239) and KDR (NC vs. 
HFHS; 1 ± 0.1463 vs. 0.4069 ± 0.05604, p = 0.0091) were significantly lower in the 
HFHS group compared to the control group (Figure 9). 
 GLRX (NC vs. HFHS; 1 ± 0.1536 vs. 0.4158 ± 0.009057, p = 0.0090) expression 
was also lower in the HFHS group (Figure 9). GLRX expression is decreased in 
ischemic muscles and skeletal muscle cells (unpublished data). The lower GLRX 
expression may indicate a hypoxic condition in tumors of the HFHS group. 
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Figure 9: 1-Week Tumor Western Blot Protein Expression. (A) Summary of western 
blot results from 1-week tumor samples. Details of individual protein expression can be 
seen in the appendix. (* = p ≤ 0.05; ** = p ≤ 0.01). (B) Western blot of 1-week tumor 
proteins that show significant difference (n = 4, each). 
 
 The 2-week tumors excised from cohort 3 showed a similar expression of proteins 
with the following expressions (Figure 10A). All 3 proteins that were significantly 
different in the 1-week tumor retained their lower trend in the HFHS group. Although 
GLRX and KDR lost their significant difference, ACTA2 continued to retain a significant 
difference (NC vs. HFHS; 1 ± 0.04624 vs. 0.5586 ± 0.1215, p = 0.0123) (Figure 10). 
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These data indicate lower EC markers (ACTA2, KDR) in tumors from the HFHS-fed 
mice. 
 
 
Figure 10: 2-Week Tumor (Cohort 3) Western Blot Protein Expression. (A) 
Summary of western blot results from 2-week tumor samples extracted from third cohort 
of mice. Details of individual protein expression can be seen in the appendix. (* = p ≤ 
0.05). (B) Western blot of ACTA2 from 2-week tumor samples (Cohort 3; n = 3, HFHS; 
n = 4, NC). 
 
 The 2-week tumors of the second cohort (n = 5, each) showed non-significant 
differences in the same angiogenic markers and proteins (Table 3, Appendix). Due to the 
inconsistency of results, the lower expression of vascular markers in diabetic tumors 
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cannot be concluded; however, it is worth reiterating that the vascularity of the tumor 
samples of the HFHS group were not increased despite the promoted tumor growth. 
 Interestingly, 2-week tumor samples from the HFHS group tended to show lower 
amounts of glutathionylated proteins compared to the NC group (Figure 11; Cohort 2, p 
= 0.0317), despite the lower trend in expressed GLRX. 1-week tumor samples (n = 4, 
each) of the HFHS group showed a slightly lower (1 ± 0.1156 vs. 0.9505 ± 0.1214), but 
not significant difference in glutathionylated proteins (p = 0.7776). 
 
 
Figure 11: 2-Week Tumor GSH Adducts (Cohort 2). (A) Western blot of GSH adducts 
from 2-week tumor samples (Cohort 2; n = 5, each). (B) Summary of 2-week tumor 
(Cohort 2; n = 5, each) western blot of GSH adducts (p = 0.0317). (* = p ≤ 0.05). 
 
 RT-qPCR analyses were performed on the 2-week tumor cohorts to examine the 
mRNA expression of angiogenic genes (PECAM1, VEGF, MMP2) and GLRX (Figure 
12). No significant difference between NC and HFHS groups were observed. 
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Figure 12: 2-Week Tumor RT-qPCR Results. (A) Summary of RT-qPCR results from 
tumor samples extracted from second cohort (n = 5, each). (B) Summary of RT-qPCR 
results from tumor samples extracted from third cohort (n = 4, NC; n = 3, HFHS). No 
significant difference was observed. Individual RT-qPCR results can be seen in the 
appendix. 
 
High Glucose Inhibits Endothelial Cell Function In Vitro. 
 In order to determine the effects of hyperglycemia (4.5 g/L) on endothelial cells, 
cell-based assays were performed to assess its effect on proliferation, migration, and 
tube-forming capabilities, using normal medium as a low-glucose control (1.0 g/L). The 
results, however, need to be verified to make a definitive conclusion. 
 Cell proliferation assay results showed that high glucose impairs endothelial cell 
proliferation (Figure 13; p = 0.1548; n = 7, each). 
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Figure 13: Endothelial Cell Proliferation Assay. High glucose inhibited endothelial 
cell proliferation (p = 0.1548; n = 7, each). 
 
 High glucose also attenuated endothelial cell migration in wound healing assays 
(Figure 14) performed both with (p = 0.3388) and without (p = 0.4071) VEGF for 
stimulation (n = 3, each). 
 
 
Figure 14: Endothelial Cell Wound Healing Assay. High glucose conditions inhibited 
endothelial cell migration both with (p = 0.3388) and without (p = 0.4071) VEGF 
stimulation (n = 3, each). 
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 Matrigel-based tube-formation assays showed the ability of endothelial cells to 
form tubes was also repressed (Figure 16). The tube formation assays were skeletonized 
and quantified for the number of nodes, junctions, meshes, segments, and branches. The 
length of the segments and branches were also quantified alongside the total length (sum 
of the length of segments, isolated elements, and branches) and the areas of the meshes 
(Figure 15). 
 
 
Figure 15: Angiogenesis Assay Analysis. Elements of the angiogenesis assay. (Elements 
used for analysis are highlighted in bold. Green = Branches; Cyan = Twigs; Magenta = 
Segments; Orange = Master Segments; Sky Blue = Meshes; Red Surrounded by Blue 
= Nodes Surrounded by Junctions Symbol; Junctions Surrounded by Red = Master 
Junctions; Blue = Isolated Elements; Cyan = Small Isolated Elements; Red Surrounded 
by Yellow = Extremities). 
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Figure 16: Matrigel-based EC Angiogenesis Assay. (A) Image of angiogenesis assay at 
2 and 5 hours (LG vs. HG). (B) Qualitative measurements of angiogenesis assay (2h, n = 
1, each). (C) Qualitative measurements of angiogenesis assay (5h, n = 1, each). 
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 Also, interestingly, high glucose medium was able to promote a 1.45-fold increase 
of GLRX expression in endothelial cells (Figure 17; n = 1, each). This data, too, should 
be replicated for confidence. 
 
 
Figure 17: Effect of High Glucose on EC GLRX Expression. (A) High glucose 
promoted 1.45-fold increase in GLRX expression. (B) Western blot of EC GLRX 
expression (LG vs. HG). 
 
 In summary, the results of the study showed that T2DM induced by a HFHS diet 
is able to promote tumor growth in both weight (2-week, p = 0.0070) and volume (1-
week, p = 0.0351; 2-week, p = 0.0002). Tumors extracted from the HFHS diet group 
showed reduced expressions of angiogenic markers (ACTA2 (1-week, p = 0.0239; 2-
week, p = 0.0123), KDR (1-week, p = 0.0091)) by western blot and a slightly reduced 
trend of angiogenesis (PECAM1) in histological analyses. GLRX expression was reduced 
in HFHS tumor samples (1-week, p = 0.0090) and, interestingly, lower amounts of GSH 
adducts (2-week, p = 0.0317) could be seen in 2-week tumors as well. In vitro studies of 
endothelial cells show reduced trends of endothelial cell function (proliferation, 
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migration, and tube formation) in high glucose medium. Also, it has been observed that 
high glucose may be able to stimulate GLRX expression in endothelial cells. 
  
	30 
DISCUSSION 
 
 The results of the following study have confirmed that B16F0 melanoma growth 
is, in fact, augmented in diet-induced diabetic mice; however, the vascular density and 
the expression of angiogenic markers from the tumor tissues did not parallel the growth 
in its size. In vitro studies suggested that high glucose can impair EC function (i.e. 
proliferation, migration, and tube formation capabilities) as well as promote GLRX 
expression, which may be related to this discrepancy. The mechanism of tumor growth in 
diabetes still lies inconclusive. 
 
The Role of Angiogenesis in Diabetic Tumor Progression. 
 Despite the significantly enhanced tumor progression, which could be observed 
through the difference in 2-week tumor weights (NC vs. HFHS; 678.5 ± 43.54 mg, n = 8 
vs. 1150 ± 147.6 mg, n = 7; p = 0.007), similar or slightly diminished trends in 
angiogenesis were observed in the tumor samples of the HFHS group (NC vs. HFHS; 
1.635 ± 0.1418 % vs. 1.342 ± 0.09972 %; p = 0.1291; n = 5, each), and results of the 
western blot showed that certain angiogenic markers, KDR (1-week, p = 0.0091) and 
ACTA2 (2-week, p = 0.0123), were also significantly lower in the tumor samples of the 
HFHS mice. Although the results may coincide with the clinical manifestation of diabetes 
that show reduced angiogenesis in certain types of tissues (Kolluru, Bir, & Kevil, 2012), 
the results are of a puzzling nature as they seemingly undermine the notion that tumor 
growth should be angiogenesis-dependent (Nishida et al., 2006; Ronca et al., 2017). 
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 The lower vascular density of the diabetic tumor samples may be the result of the 
impaired EC function (Zhu et al., 2015) and EC-GLRX expression observed in the 
hyperglycemia experiments in vitro. GLRX has been shown to be upregulated in diabetic 
rat tissue in vivo alongside high glucose experiments in vitro (Shelton et al., 2007). As 
GLRX is an NF-κB dependent gene (Aesif et al., 2011), the hyperglycemic environment 
alongside the inflammation associated with DM may have stimulated a higher level of 
GLRX to be expressed by endothelial cells in vivo, which could have decreased their 
migration capabilities (Cohen et al., 2016; Murdoch et al., 2014; Watanabe et al., 2016). 
 Thrombospondin-1 (THBS1) is another protein of interest that is shown to be 
implicated in the development of diabetic conditions and inhibited with hyperglycemia 
(Bhattacharyya et al., 2012). THBS1 is a potent endogenous inhibitor of angiogenesis 
(Bhattacharyya et al., 2012) and has been shown to be decreased in cancers where 
angiogenesis is increased (Stenina-Adognravi, 2014). miR-467, a tissue-specific 
transcriptional suppressor of THBS1, has been shown to be upregulated in hyperglycemic 
conditions in vivo, and also in tissues that are associated with increased angiogenesis in 
diabetic patients (Bhattacharyya et al., 2012; Krukovets et al., 2015). It is plausible that 
the non-significant difference between the angiogenesis of the two groups may be related 
to the close interplay between proangiogenic (e.g. miR-467) and antiangiogenic factors 
(e.g. GLRX). 
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EC-GLRX Expression May Be Related to Similar Vascular Density and Augmented 
Tumor Growth. 
 Another model in which augmented tumor growth can be seen without increased 
vascular density is a model of EC-specific GLRX-overexpressing transgenic mice 
(Matsui et al., 2017). Still under investigation, EC-specific GLRX-overexpressing 
transgenic mice were similarly implanted with subcutaneous B16F0 melanoma cells to 
test the hypothesis that decreased endothelial cell migration due to GLRX overexpression 
might hinder the growth of tumors. Interestingly enough, the mice of the transgenic study 
have shown to paradoxically exhibit an increased tumor growth, much like the diabetic 
mouse model, despite significantly decreased angiogenesis upon histological analysis of 
PECAM1 staining (n = 6, WT; n = 5, EC-GLRX TG; p < 0.05) (Figure 18). 
 
 
Figure 18: % Area of PECAM1 Staining (WT vs. EC-GLRX TG). Tumor samples 
extracted from EC-GLRX TG mice (n = 5) show a significantly lower density of 
PECAM1 staining compared to the wild-type (WT) (n = 6). (* = p < 0.05). 
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 The in vitro high glucose experiments of the current study shows that it may be 
plausible that endothelial cells might be expressing higher levels of GLRX with diabetes 
in vivo, resulting in a similar outcome as those observed in the transgenic mice. 
 
Tumor Cells May Be Displaying Vasculogenic Mimicry (VM) to Compensate for 
Impaired Angiogenesis. 
 If the above is true, and endothelial cells are, indeed, overexpressing GLRX in a 
diabetic system, the multiplex symptoms of diabetes can become more easily narrowed 
down to a single factor, i.e. hindered angiogenesis. Vascoulogenic mimicry is a concept 
in which certain malignant tumor cells have to potential to form vessel-like structures de 
novo and even differentiate into having EC-like capabilities if the blood supply is not 
sufficient (Delgado-Bellido et al., 2017; Qiao et al., 2015). Although the initial 
morphological, clinical, and molecular characterization of VM was carried out using 
human melanoma cells as a model, VM has also been observed in various malignant 
tumors, including glioblastoma, osteosarcoma, gallbladder, ovarian, lung, hepatocellular, 
breast, prostate, and gastric cancer, to name a few (Delgado-Bellido et al., 2017; Qiao et 
al., 2015). 
 If vasculogenic mimicry is present in the current study, it is plausible that tumor 
cells of the HFHS group may be expressing VM to compensate for the reduced blood 
supply and angiogenesis. The VM, that may not otherwise be as promoted in the control 
group, may be contributing to the augmented tumor growth in the diabetic model. 
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 There are several methods to identify VM vessels, including PECAM1 - / PAS +, 
Dextran + / PECAM1 -, or even simple H & E staining of vessel-like structures without 
an EC-lined lumen (Delgado-Bellido et al., 2017; Qiao et al., 2015); however, the 
assessment of the qualitative characteristics of such structures still lie obscure as VM is a 
fairly newly discovered phenomenon. Interesting to note, however, is that WNT family 
member 5A (WNT5A) is known as one of the inducers for VM (Delgado-Bellido et al., 
2017). WNT5A has previously been shown to be upregulated with diabetes (Aesif et al., 
2011; Shelton et al., 2007) and GLRX overexpression through a positive feedback of the 
GLRX- NF-κB-WNT5A pathway (Murdoch et al., 2014). The corollary to these studies 
suggest that VM may be taking place in tumor samples of the T2DM mouse model. 
Further studies are required to elucidate this occurrence. 
 
Other Possible Explanations for Enhanced Tumor Growth. 
 Type II diabetes mellitus, in likewise to cancer, is a complex multifactorial 
disorder that displays an array of different concomitant symptoms (Vigneri et al., 2009). 
Specifically, alongside hyperglycemia, obesity, inflammation, and insulin resistance are 
few of the many concurring symptoms of diabetes (American Diabetes Association, 
2010; Centers for Disease Control and Prevention, 2017). In fact, cancer and T2DM share 
many of the same risk factors in the pathogeneses of the two diseases, such as aging, 
obesity, diet, and physical inactivity (Giovannucci et al., 2010). Because of such nature, 
the association between cancer and T2DM is that of a complex intertwined relationship. 
Possible mechanisms for the augmentation of cancer growth in T2DM include, but are 
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not limited to, hyperinsulinemia, hyperglycemia, inflammation, and adipokine secretion 
disturbances (Tahergorabi & Khazaei, 2012). Differences in diet may also lead to nutrient 
discrepancies, whereby tumor cells may be able to receive a more efficient and/or 
enriched nutrition to support its progression, which may also play a role in the 
augmentation of tumor sizes despite similar angiogenesis. 
 
Limitations and Future Directions. 
 As stated above, since diabetes, specifically T2DM, is a complicated 
multifactorial condition. The following study has its limitations in aiming to focus on 
hyperglycemia, which represents just one of the multiple conjoining aspects and clinical 
manifestations of diabetes. 
 Cell-based assays were performed using HDMVEC instead of murine endothelial 
cells. If ECs were isolated from tumors, the diabetic EC from the tumor samples could 
have been characterized in detail (e.g. EC population, gene expression). Fluorescence 
activated cell sorting (FACS) methods have been attempted to isolate endothelial cells 
from the tumor samples (van Beijnum, Rousch, Castermans, van der Linden, & Griffioen, 
2008); however, the population of endothelial cells in the tumor samples (approximately 
1.5% of total mass by immunohistochemistry) posed a difficulty in the isolation, as the 
cell count was even lower after sorting. More specific markers and efficient methods for 
FACS isolation techniques need to be studied. 
 Future directions of this study should be aimed towards the explanation of the 
enhanced tumor growth in T2DM mice despite the similar vascular densities which were 
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observed to the control. Studies on the tumor samples should focus on markers pointed 
out through the discussion such as TBSP1 and WNT5A. Cadherin 5 (CDH5) may also be 
of significant interest, as the protein has been indicated to exhibit a particular functional 
significance in the VM of highly aggressive melanoma cells (Hendrix et al., 2001). In 
vitro endothelial cell studies should focus on the isolation of murine endothelial cells 
from tumor samples and verifying the effects of hyperglycemia on endothelial cell 
function and GLRX expression. The possibility of vasculogenic mimicry cannot be 
overlooked and histological analyses alongside FACS analyses could be the basis to 
understanding the presence of such phenomenon. 
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APPENDIX 
 
Table 1. Tumor Measurements. 
ID Tumor Measurements 
Cohort & 
Diet 
Mouse 
Number 
Incubation 
Period 
Weight 
(mg) 
L 
(mm) 
W 
(mm) 
H 
(mm) 
V 
(mm3) 
1 
(Pilot) 
N 
C 
602-R 2 Weeks 3013.0 22.51 24.7 13.2 3842.8 
602-L 2 Weeks 1365.0 14.5 18.9 7.3 1047.5 
606-R 2 Weeks 519.0 13.47 8.84 6.89 429.6 
606-L 2 Weeks 2482.0 15.5 17.1 11.5 1596.0 
610-R 2 Weeks 2060.0 19.33 19.33 9.3 1819.5 
H 
F 
H 
S 
618-R 2 Weeks 2468.0 22.02 17.45 11.95 2404.2 
618-L 2 Weeks 1261.0 15 10.52 7.84 647.8 
626-R 2 Weeks 444.0 12.14 10.92 6.68 463.7 
622-R 2 Weeks 996.0 18.24 11.27 11.5 1237.6 
622-L 2 Weeks 799.0 12.2 29.72 6.07 1152.4 
2 
N 
C 
610-L 2 Weeks 615.0 17.3 6.8 5.6 344.9 
614-R 2 Weeks 818.0 19.4 10.8 5.9 647.3 
614-L 2 Weeks 572.0 8.0 16.4 5.5 377.8 
590-R 2 Weeks 499.0 20.4 7.4 3.7 292.5 
590-L 2 Weeks 633.0 10.4 14.2 7.9 610.9 
H 
F 
H 
S 
630-R 2 Weeks 1421.0 24.8 14.4 10.2 1907.3 
630-L 2 Weeks 1296.0 22.7 14.6 8.5 1475.0 
594-R 2 Weeks 1003.0 18.5 13.9 9.4 1265.6 
594-L 2 Weeks 646.0 16.3 12.2 8.5 887.0 
626-L 2 Weeks 621.0 14.1 12.2 8.6 774.6 
3 
N 
C 
983N 2 Weeks 860.0 10.4 7.3 15.2 604.2 
984R 2 Weeks 689.5 17.3 10.4 8.1 763.1 
985R 2 Weeks 741.6 8.3 5.9 18.5 474.4 
985N 2 Weeks 2516.0 * 15.6 21.4 12.3 2150.0 * 
H 
F 
H 
S 
976R 2 Weeks 1594.1 14.3 20.8 11.6 1806.6 
976N 2 Weeks 1471.0 16.0 18.1 8.7 1319.2 
977R 2 Weeks 2985.0 * 30.1 18.1 11.4 3252.0 * 
977N ** 2 Weeks N/A N/A N/A N/A N/A 
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Table 1. Tumor Measurements (Continued). 
ID Tumor Measurements 
Cohort & 
Diet 
Mouse 
Number 
Incubation 
Period 
Weight 
(mg) 
L 
(mm) 
W 
(mm) 
H 
(mm) 
V 
(mm3) 
4 
N 
C 
984N 1 Week 83.1 4.4 4.5 2.2 22.8 
986R 1 Week 107.8 7.9 5.4 1.9 42.4 
986N 1 Week 66.5 7.5 4.2 1.6 26.4 
987N 1 Week 136.4 6.3 4.8 3.4 53.8 
H 
F 
H 
S 
978N 1 Week 119.0 7.6 9.3 3.1 114.7 
979R 1 Week 158.4 4.9 17.2 3.5 154.5 
979N 1 Week 140.5 7.6 10.1 2.2 88.4 
829N 1 Week 111.8 8.0 8.5 1.3 46.3 
* = Significant outliers (p < 0.05) were omitted in the analyses of results. 
** = Mouse was found dead 1-week post-implantation. 
 
Table 2. Protein Expression in 1-Week Tumor Samples. 
Protein of Interest NC (n = 4) HFHS (n = 4) p 
ACTA2 * 1 ± 0.1328 0.495 ± 0.103 0.0239 
CD68 1 ± 0.1352 0.6834 ± 0.02389 0.0607 
GLRX ** 1 ± 0.1536 0.4158 ± 0.009057 0.009 
HIF1A 1 ± 0.2547 0.6745 ± 0.08145 0.2691 
KDR ** 1 ± 0.1463 0.4069 ± 0.05604 0.0091 
PECAM1 1 ± 0.1083 0.6824 ± 0.1351 0.1163 
VEGFA 1 ± 0.1265 1.036 ± 0.1371 0.8549 
GSH Adducts 1 ± 0.1156 0.9505 ± 0.1214 0.7776 
* = p ≤ 0.05, ** = p ≤ 0.01. 
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Table 3. Protein Expression in 2-Week Tumor Samples (Cohort 2). 
Protein of Interest NC (n = 5) HFHS (n = 5) p 
ACTA2 1 ± 0.3044 0.8683 ± 0.1555 0.7101 
CD68 1 ± 0.1536 1.192 ± 0.1999 0.4692 
GLRX 1 ± 0.1748 1.491 ± 0.2755 0.1711 
HIF1A 1 ± 0.1447 1.056 ± 0.2827 0.8649 
KDR 1 ± 0.1239 1.046 ± 0.1508 0.8188 
PECAM1 1 ± 0.1486 1.555 ± 0.2492 0.0919 
VEGFA 1 ± 0.09522 0.9024 ± 0.08169 0.4591 
GSH Adducts * 1 ± 0.0864 0.6992 ± 0.07698 0.0317 
* = p ≤ 0.05. 
 
Table 4. Protein Expression in 2-Week Tumor Samples (Cohort 3). 
Protein of Interest NC (n = 4) HFHS (n = 3) p 
ACTA2* 1 ± 0.04624 0.5586 ± 0.1215 0.0123 
CD68 1 ± 0.1803 1.168 ± 0.6235 0.7771 
GLRX 1 ± 0.2364 0.3754 ± 0.0573 0.079 
HIF1A 1 ± 0.1431 0.7946 ± 0.2065 0.4346 
KDR 1 ± 0.2987 0.3465 ± 0.1064 0.1329 
PECAM1 1 ± 0.1961 0.8245 ± 0.2439 0.5945 
VEGFA 1 ± 0.1094 0.6364 ± 0.08081 0.0552 
GSH Adducts 1 ± 0.1297 0.9243 ± 0.2243 0.7675 
* = p ≤ 0.05. 
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Table 5. 2-Week Tumor RT-qPCR Results (Pilot Cohort). 
Protein of Interest NC (n = 5) HFHS (n = 5) p 
ANGPT2 1 ± 0.1603 1.618 ± 0.4319 0.2169 
FLT1 1 ± 0.124 1.171 ± 0.2537 0.5623 
GLRX 1 ± 0.1581 0.9491 ± 0.1799 0.8371 
HIF1A 1 ± 0.05256 0.9255 ± 0.03067 0.2557 
MMP2 * 1 ± 0.3359 2.499 ± 0.4472 0.0279 
PECAM1 * 1 ± 0.1874 1.817 ± 0.2834 0.0429 
TXN 1 ± 0.07965 0.8442 ± 0.07344 0.1882 
VEGFA 1 ± 0.1465 1.032 ± 0.1266 0.872 
Results of the pilot cohort may not be reliable as results from the latter cohorts. 
Tumors exhibited severe skeletal muscle and skin invasion at the time of extraction. 
* = p ≤ 0.05. 
 
Table 6. 2-Week Tumor RT-qPCR Results (Cohort 2). 
Protein of Interest NC (n = 5) HFHS (n = 5) p 
GLRX 1 ± 0.03231 1.076 ± 0.1492 0.6341 
MMP2 1 ± 0.1184 1.084 ± 0.2676 0.7825 
PECAM1 1 ± 0.2262 0.9596 ± 0.2222 0.9017 
VEGFA 1 ± 0.2243 0.8201 ± 0.1764 0.5459 
 
Table 7. 2-Week Tumor RT-qPCR Results (Cohort 3). 
Protein of Interest NC (n = 4) HFHS (n = 3) p 
GLRX 1 ± 0.08909 0.9303 ± 0.1059 0.6341 
MMP2 1 ± 0.1464 0.8384 ± 0.07897 0.4233 
PECAM1 1 ± 0.2168 1.264 ± 0.241 0.4551 
VEGFA 1 ± 0.2857 1.178 ± 0.5125 0.7581 
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